Next 10 |
home / stock / soltf / soltf news
Tokyo, Japan and Cambridge, UK, 17 April 2024 – Nxera Pharma Co. Ltd (“Nxera” or “the Company; TSE 4565) – formerly known as Sosei Group or Sosei Heptares – announces that it has decided to issue new shares (“the Share Issuance”) under the...
NBI-1117568 is an oral, selective muscarinic M4 receptor agonist advancing through Phase 2 clinical development under a multi-program collaboration with Neurocrine Biosciences Successful completion of a long-term preclinical toxicity program to support safe, chronic dosing of NBI-1117568 in f...
PIVLAZ™ is the first drug approved in South Korea for the prevention of Cerebral Vasospasm in patients with Aneurysmal Subarachnoid Hemorrhage (aSAH) PIVLAZ™ will become commercially available in South Korea in early 2025 Tokyo, Japan and Cambridge, UK, 1 5 April...
Nxera Pharma to represent WODA in Japan and South Korea WODA offers a ‘one-stop’ solution for biopharma companies seeking to commercialize rare or orphan medicines across global markets Tokyo, Japan and Cambridge, UK, 8 April 2024 – Nxera Pharma Co. Ltd ...
Tokyo, Japan and Cambridge, UK, 3 April 2024 - Nxera Pharma (“Nxera” or “the Company”; TSE: 4565) – formerly known as Sosei Group or Sosei Heptares – today announces the appointment of Japan pharmaceutical sector expert, Mr. Patrick Branch, as Head of B...
New name expresses the Company’s vision to lead the next era of medicine - from Japan, for Japan, and by extension, to the world – and its mission to accelerate the development of life-changing medicines, by investing in science and technology Sosei Group and its subsidiaries, H...
Tokyo, Japan and Cambridge, UK, 27 March 2024 – Sosei Group Corporation (“the Company”; TSE: 4565) announces that the re-election of its Board of Directors and Executive Officers was approved at the Company’s 34th Annual Shareholders’ Meeting and a sub...
HTL0033744 has been designed by Sosei Heptares to promote mucosal healing and resolve inflammation in people with IBD Tokyo, Japan and Cambridge, UK, 21 March 2024 – Sosei Group Corporation (“Sosei Heptares” or “the Company”; TSE: 4565) announces...
GPR35 is a novel target with an established genetic association to IBD UK regulatory approval received to commence first-in-human studies Return of rights follows change in immunology research strategy by GSK Tokyo, Japan and Cambridge, UK, 21 March 2024 – Sos...
Single-target agreement focused on development of novel, small molecule agonists of GPR52 discovered by Sosei Heptares with the potential to simultaneously address positive, negative and cognitive symptoms of schizophrenia Sosei Heptares will receive EUR 25 million upfront from Boehringer...
News, Short Squeeze, Breakout and More Instantly...
Sosei Co Ltd Ord Company Name:
SOLTF Stock Symbol:
OTCMKTS Market:
Tokyo, Japan and Cambridge, UK, 17 April 2024 – Nxera Pharma Co. Ltd (“Nxera” or “the Company; TSE 4565) – formerly known as Sosei Group or Sosei Heptares – announces that it has decided to issue new shares (“the Share Issuance”) under the...
NBI-1117568 is an oral, selective muscarinic M4 receptor agonist advancing through Phase 2 clinical development under a multi-program collaboration with Neurocrine Biosciences Successful completion of a long-term preclinical toxicity program to support safe, chronic dosing of NBI-1117568 in f...
PIVLAZ™ is the first drug approved in South Korea for the prevention of Cerebral Vasospasm in patients with Aneurysmal Subarachnoid Hemorrhage (aSAH) PIVLAZ™ will become commercially available in South Korea in early 2025 Tokyo, Japan and Cambridge, UK, 1 5 April...